Innovative new treatments with the potential to improve patients’ lives face unprecedented obstacles, including greater complexity and cost, more stringent evidence requirements to secure patient access beyond regulatory approval, a greater diversity of stakeholders and decision-makers, and competition for share of voice.
Thus, stakeholder engagement – whether with HCPs, patients, regulators, advocates, or payers – has become increasingly science-based and evidence-driven. Generating actionable evidence, including RWE and HEOR data, in a timely manner has become a key objective. Further, the ability to anticipate, shape and optimize product development has become one of the most critical success factors for realizing an innovation’s full promise.
Through illustrative case studies and expert panel discussion, this session will uncover how integrated evidence generation planning – beginning early in the product development lifecycle – can optimize an asset’s value story, and lead to greater clinical and commercial success and improved patient outcomes.
Key learning objectives:
- LEARN strategies for optimizing integrated evidence generation planning to ensure commercial success and improved patient outcomes.
- EXPLORE case studies illustrating best practices for optimizing an asset’s value story through stakeholder engagement.
- UNDERSTAND the importance of breaking down silos to achieve internal sponsor alignment on strategic imperatives and evidentiary needs.
